Alnylam Pharmaceuticals, Inc. (ALNY) Given “Buy” Rating at Cowen and Company
Cowen and Company restated their buy rating on shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in a research report report published on Thursday. The brokerage currently has a $151.00 price objective on the biopharmaceutical company’s stock.
A number of other research firms have also weighed in on ALNY. Goldman Sachs Group, Inc. (The) raised shares of Alnylam Pharmaceuticals from a neutral rating to a buy rating and upped their target price for the stock from $62.00 to $163.00 in a report on Monday, October 2nd. Jefferies Group LLC set a $102.00 target price on shares of Alnylam Pharmaceuticals and gave the stock a buy rating in a report on Friday, August 25th. B. Riley decreased their target price on shares of Alnylam Pharmaceuticals to $220.00 and set a buy rating on the stock in a report on Wednesday. Barclays PLC upped their target price on shares of Alnylam Pharmaceuticals from $50.00 to $70.00 and gave the stock an equal weight rating in a report on Thursday, August 10th. Finally, BMO Capital Markets reaffirmed an outperform rating and set a $99.00 target price (down previously from $105.00) on shares of Alnylam Pharmaceuticals in a report on Wednesday, September 6th. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and seventeen have issued a buy rating to the company. Alnylam Pharmaceuticals currently has an average rating of Buy and a consensus price target of $114.57.
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded up $2.30 during trading on Thursday, reaching $139.98. 1,386,900 shares of the company were exchanged, compared to its average volume of 1,120,946. The company has a debt-to-equity ratio of 0.14, a quick ratio of 8.84 and a current ratio of 9.83. Alnylam Pharmaceuticals has a twelve month low of $35.98 and a twelve month high of $147.63.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.23) by ($0.11). The firm had revenue of $17.10 million for the quarter, compared to the consensus estimate of $28.15 million. Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. The business’s revenue was up 24.8% on a year-over-year basis. During the same period last year, the company posted ($1.21) EPS. research analysts expect that Alnylam Pharmaceuticals will post -5.18 EPS for the current year.
In other Alnylam Pharmaceuticals news, Director Dennis A. Ausiello sold 20,000 shares of the stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $130.00, for a total transaction of $2,600,000.00. Following the completion of the sale, the director now owns 20,000 shares of the company’s stock, valued at approximately $2,600,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Akshay Vaishnaw sold 33,666 shares of the stock in a transaction on Monday, October 30th. The shares were sold at an average price of $121.46, for a total transaction of $4,089,072.36. Following the sale, the executive vice president now directly owns 45,201 shares of the company’s stock, valued at approximately $5,490,113.46. The disclosure for this sale can be found here. Insiders have sold a total of 215,797 shares of company stock valued at $25,035,072 in the last three months. 4.30% of the stock is currently owned by corporate insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. State of Wisconsin Investment Board boosted its position in Alnylam Pharmaceuticals by 0.7% during the 2nd quarter. State of Wisconsin Investment Board now owns 15,012 shares of the biopharmaceutical company’s stock valued at $1,197,000 after buying an additional 100 shares during the period. The Manufacturers Life Insurance Company boosted its position in Alnylam Pharmaceuticals by 7.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 167 shares during the period. Prudential Financial Inc. boosted its position in Alnylam Pharmaceuticals by 4.8% during the 2nd quarter. Prudential Financial Inc. now owns 4,404 shares of the biopharmaceutical company’s stock valued at $351,000 after buying an additional 200 shares during the period. Utah Retirement Systems lifted its position in shares of Alnylam Pharmaceuticals by 1.5% in the 2nd quarter. Utah Retirement Systems now owns 13,800 shares of the biopharmaceutical company’s stock worth $1,100,000 after purchasing an additional 200 shares during the period. Finally, Alliancebernstein L.P. lifted its position in shares of Alnylam Pharmaceuticals by 0.8% in the 2nd quarter. Alliancebernstein L.P. now owns 47,873 shares of the biopharmaceutical company’s stock worth $3,818,000 after purchasing an additional 398 shares during the period. 94.20% of the stock is owned by institutional investors and hedge funds.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.